Company intelligence / Profile preview

intoDNA

Ownership: Private
Development stage: Commercial

Overview

intoDNA has developed STRIDE™, a proprietary platform for highly sensitive detection of single-strand and double-strand DNA lesions at the individual break level. The technology enables precise quantification of DNA damage in various biological materials, supporting biomarker discovery, mechanism-of-action studies, pharmacodynamics assessment, patient selection strategies, and functional validation of drug candidates. The company collaborates with major pharmaceutical companies—including several top ten pharma—and biotechs worldwide.

Therapeutic areas: Oncology
Industry: Molecular Diagnostics

Partnerships

AstraZenecaMultiple top pharmaceutical companies

Beyond the preview

Go deeper on intoDNA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on intoDNA.

Explore the full profile